{"component": "definition", "props": {"groups": [{"snippet": "means Knight Therapeutics Inc., a corporation incorporated under the laws of Canada.", "snippet_links": [{"key": "a-corporation", "type": "clause", "offset": [32, 45]}, {"key": "the-laws", "type": "definition", "offset": [65, 73]}], "samples": [{"hash": "ih9adbPOFd", "uri": "/contracts/ih9adbPOFd#therapeutics", "label": "Indenture (Endo International PLC)", "score": 26.5167693361, "published": true}, {"hash": "llRXykv6UIC", "uri": "/contracts/llRXykv6UIC#therapeutics", "label": "Indenture (Endo International PLC)", "score": 26.0704996578, "published": true}, {"hash": "gJ17t3F3xC8", "uri": "/contracts/gJ17t3F3xC8#therapeutics", "label": "Indenture (Endo International PLC)", "score": 25.4955509925, "published": true}], "size": 8, "hash": "c0534ba5d82a18d0bc8ef87b8ea02f72", "id": 1}, {"snippet": "means use as a therapeutic agent in humans or animals.", "snippet_links": [{"key": "therapeutic-agent", "type": "definition", "offset": [15, 32]}], "samples": [{"hash": "iGajYRUKAvJ", "uri": "/contracts/iGajYRUKAvJ#therapeutics", "label": "Exclusive License Agreement (Prothena Corp PLC)", "score": 29.6242299795, "published": true}, {"hash": "3gAhZPm3SWG", "uri": "/contracts/3gAhZPm3SWG#therapeutics", "label": "Exclusive License Agreement (Prothena Corp PLC)", "score": 29.3504449008, "published": true}, {"hash": "ggWzV6DNN5I", "uri": "https://d18rn0p25nwr6d.cloudfront.net/CIK-0001559053/ae6ab6b1-0a4c-47d6-88c1-a6bd26eff5f5.pdf", "label": "d18rn0p25nwr6d.cloudfront.net", "score": 11.1834360027, "published": false}], "size": 6, "hash": "f45074939400deef066a11f4c2194d9a", "id": 2}, {"snippet": "means Knight Therapeutics, a corporation organized under the laws of Canada.", "snippet_links": [{"key": "a-corporation", "type": "clause", "offset": [27, 40]}, {"key": "the-laws", "type": "definition", "offset": [57, 65]}], "samples": [{"hash": "araseMlU9nt", "uri": "/contracts/araseMlU9nt#therapeutics", "label": "Credit Agreement (Endo International PLC)", "score": 26.4510609172, "published": true}, {"hash": "8XMFUsV4WA8", "uri": "/contracts/8XMFUsV4WA8#therapeutics", "label": "Credit Agreement (Endo International PLC)", "score": 25.1587953457, "published": true}, {"hash": "1ylzmf7VR4K", "uri": "/contracts/1ylzmf7VR4K#therapeutics", "label": "Supplemental Indenture (Endo International PLC)", "score": 25.1587953457, "published": true}], "size": 6, "hash": "6ab76e5dc69e244732025cb9db627bb0", "id": 3}, {"snippet": "means the field of therapeutics.", "snippet_links": [{"key": "field-of", "type": "definition", "offset": [10, 18]}], "samples": [{"hash": "6XhUdEbdE8X", "uri": "/contracts/6XhUdEbdE8X#therapeutics", "label": "Cross License Agreement (Mirna Therapeutics, Inc.)", "score": 26.6427104723, "published": true}, {"hash": "8ukgi9cJC7V", "uri": "/contracts/8ukgi9cJC7V#therapeutics", "label": "Cross License Agreement (Mirna Therapeutics, Inc.)", "score": 25.2546201232, "published": true}, {"hash": "5C9VTVsUnkK", "uri": "https://investor.synlogictx.com/static-files/b6757bc1-032a-414e-843d-bc5b6029d4c6", "label": "Amendment", "score": 13.9637234771, "published": false}], "size": 3, "hash": "445cb18934e42068b3a157020f4c4384", "id": 4}, {"snippet": "means Biohaven Therapeutics Ltd., a British Virgin Islands business company limited by shares with BVI company number 1916121 incorporated under the laws of the British Virgin Islands and a direct wholly owned Subsidiary of the Company.", "snippet_links": [{"key": "british-virgin-islands", "type": "clause", "offset": [36, 58]}, {"key": "company-limited", "type": "clause", "offset": [68, 83]}, {"key": "bvi-company", "type": "definition", "offset": [99, 110]}, {"key": "the-laws", "type": "definition", "offset": [145, 153]}, {"key": "subsidiary-of-the-company", "type": "definition", "offset": [210, 235]}], "samples": [{"hash": "9v17Uy988NY", "uri": "/contracts/9v17Uy988NY#therapeutics", "label": "Separation and Distribution Agreement (Biohaven Research Ltd.)", "score": 33.605065024, "published": true}, {"hash": "gHkmyRymL59", "uri": "/contracts/gHkmyRymL59#therapeutics", "label": "Separation and Distribution Agreement (Biohaven Research Ltd.)", "score": 33.4955509925, "published": true}, {"hash": "edYeNSNMfSx", "uri": "/contracts/edYeNSNMfSx#therapeutics", "label": "Separation and Distribution Agreement (Biohaven Pharmaceutical Holding Co Ltd.)", "score": 31.3559206023, "published": true}], "size": 3, "hash": "ea742f0560e7a7d8b047e4bd62a43a77", "id": 5}, {"snippet": "means any Compound(s) which is a \u201cdrug\u201d as defined in the U.S. Food, Drug and Cosmetic Act and any Compound(s) for the therapeutic treatment of any human disease or condition, which requires FDA approval of a NDA for claims of safety or efficacy.", "snippet_links": [{"key": "the-us", "type": "clause", "offset": [54, 61]}, {"key": "treatment-of", "type": "definition", "offset": [131, 143]}, {"key": "approval-of", "type": "definition", "offset": [195, 206]}, {"key": "claims-of", "type": "clause", "offset": [217, 226]}], "samples": [{"hash": "7o1p4zmE9fC", "uri": "/contracts/7o1p4zmE9fC#therapeutics", "label": "Collaborative Research, Development, Commercialization and License Agreement (Senomyx Inc)", "score": 29.6187542779, "published": true}, {"hash": "1JVi5bSNM9f", "uri": "/contracts/1JVi5bSNM9f#therapeutics", "label": "Collaborative Research, Development, Commercialization and License Agreement (Senomyx Inc)", "score": 29.180698152, "published": true}], "size": 2, "hash": "5b8377f13772471a0338f5f0bad2fa3a", "id": 6}, {"snippet": "means any [\u2026***\u2026].", "snippet_links": [], "samples": [{"hash": "l2g4kjO1JeL", "uri": "/contracts/l2g4kjO1JeL#therapeutics", "label": "Collaborative Research, Development, Commercialization and License Agreement", "score": 31.340862423, "published": true}, {"hash": "9SMyW8f1Het", "uri": "/contracts/9SMyW8f1Het#therapeutics", "label": "Collaborative Research, Development, Commercialization and License Agreement (Senomyx Inc)", "score": 24.5811088296, "published": true}], "size": 2, "hash": "08fe725d0094a21d64286a51683dc3ba", "id": 7}, {"snippet": "means any Compound(s) which [***].", "snippet_links": [], "samples": [{"hash": "snd5arEmAd", "uri": "/contracts/snd5arEmAd#therapeutics", "label": "Collaborative Research, Development, Commercialization and License Agreement (Senomyx Inc)", "score": 21.8405201916, "published": true}], "size": 2, "hash": "82eb33bbdac953b8ec77cf1f567a48ea", "id": 8}, {"snippet": "means RVX Therapeutics Inc., a corporation incorporated under the ABCA and, prior to giving effect to the Arrangement, a wholly-owned subsidiary of Resverlogix;", "snippet_links": [{"key": "a-corporation", "type": "clause", "offset": [29, 42]}, {"key": "prior-to", "type": "clause", "offset": [76, 84]}, {"key": "giving-effect-to-the-arrangement", "type": "clause", "offset": [85, 117]}, {"key": "subsidiary-of", "type": "definition", "offset": [134, 147]}], "samples": [{"hash": "9Pllmvb765f", "uri": "https://taxinterpretations.com/wp-content/uploads/2012/09/Resverlogix1May2013.pdf", "label": "Notice", "score": 10.6646132786, "published": false}], "size": 1, "hash": "49de3b3777ff4130107edf6e9e2a0fed", "id": 9}, {"snippet": "means treatments or therapies;", "snippet_links": [], "samples": [{"hash": "f7eR44lbvNv", "uri": "https://investors.puretechhealth.com/static-files/8981a36e-33b4-4d64-83d8-e00153d16f0d", "label": "investors.puretechhealth.com", "score": 9.8466803559, "published": false}], "size": 1, "hash": "d8318239bb4b4bc70f2f46dbde1e8d45", "id": 10}], "next_curs": "ClkSU2oVc35sYXdpbnNpZGVyY29udHJhY3RzcjULEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIVdGhlcmFwZXV0aWNzIzAwMDAwMDBhDKIBAmVuGAAgAA==", "definition": {"snippet": "means Knight Therapeutics Inc., a corporation incorporated under the laws of Canada.", "size": 37, "title": "Therapeutics", "id": "therapeutics", "examples": ["Certain confidential information contained in this document, marked by [**], has been omitted because ADC <strong>Therapeutics</strong> SA (ADCT) has determined that the information (i) is not material and (ii) would likely cause competitive harm to ADC <strong>Therapeutics</strong> SA (ADCT) if publicly disclosed.", "P.O. Box 21870 Lehigh Valley, PA 18002-1870 Blue Cross &amp; Blue Shield of Rhode Island Dental Claims Administrator P.O. Box 69427 Harrisburg, PA 17106-9427 Blue Cross Vision c/o EyeMed Vision Care Attn: OON Claims P.O. Box 8504 Mason, OH 45040-7111 Mailing address to submit an appeal: Blue Cross &amp; Blue Shield of Rhode Island Grievance and Appeals \u2587\u2587\u2587\u2587 \u2587\u2587\u2587 \u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587 \u2587\u2587\u2587\u2587\u2587\u2587 \u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587, \u2587\u2587 \u2587\u2587\u2587\u2587\u2587 Prime <strong>Therapeutics</strong>, LLC.", "The Contractor shall also participate in meetings and proceedings with external entities as directed by FSSA, including but not limited to, the DUR Board, MHQAC, Medicaid Advisory Committee, <strong>Therapeutics</strong> Committee, Indiana Psychotropic Medication Advisory Committee and legislative hearings.", "P.O. Box 21870 Lehigh Valley, PA 18002-1870 Blue Cross &amp; Blue Shield of Rhode Island Dental Claims Administrator P.O. Box 69427 Harrisburg, PA 17106-9427 Blue Cross Vision c/o EyeMed Vision Care Attn: OON Claims P.O. Box 8504 Mason, OH 45040-7111 Mailing address to submit an appeal: Blue Cross &amp; Blue Shield of Rhode Island Grievance and Appeals Unit \u2587\u2587\u2587 \u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587 \u2587\u2587\u2587\u2587\u2587\u2587 \u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587, \u2587\u2587 \u2587\u2587\u2587\u2587\u2587 Prime <strong>Therapeutics</strong>, LLC.", "The medications and related products listed on a Formulary are determined by a Pharmacy and <strong>Therapeutics</strong> (P &amp; T) Committee or an equivalent entity.", "The Contractor shall utilize a Pharmacy and <strong>Therapeutics</strong> Committee which shall meet regularly to make recommendations for changes to the PDL and/or formulary.", "The Contractor shall utilize a Pharmacy and <strong>Therapeutics</strong> Committee which shall meet regularly to make recommendations for changes to non-formulary covered outpatient drugs.", "Common Stock Purchase Warrant Issued by Mateon <strong>Therapeutics</strong>, Inc.", "All notices, requests, demands and other communications hereunder shall be in writing and shall be deemed duly given when delivered by hand, or when delivered if mailed by registered or certified mail, postage prepaid, return receipt requested, or private courier service or via facsimile (with written confirmation of receipt) or email (with written confirmation of receipt) as follows: If to Employer, to: Aclaris <strong>Therapeutics</strong>, Inc.", "All notices, requests, consents and other communications hereunder shall be in writing, shall be addressed to the receiving party\u2019s address as follows: If to the Company: PTC <strong>Therapeutics</strong> Inc."], "related": [["therapeutic-care", "Therapeutic care", "Therapeutic care"], ["radiologic-technologist-limited", "Radiologic technologist, limited", "Radiologic technologist, limited"], ["pharmaceutical-care", "Pharmaceutical care", "Pharmaceutical care"], ["solutions", "Solutions", "Solutions"], ["information-technologies", "Information Technologies", "Information Technologies"]], "related_snippets": [], "updated": "2025-07-07T00:16:47+00:00"}, "json": true, "cursor": ""}}